Risk factor
High price volatility
Profitability factor
Favourable analyst view
About
BINEX Co., Ltd. operates as a pharmaceutical enterprise based in South Korea. The company provides an extensive array of medicinal products, encompassing bisroot items, gastrointestinal treatments (including antispasmodics and antiulcerants), NSAIDs, cardiovascular and urology medications, hepatic protective agents, topical ointments and creams, ophthalmic solutions, CNS agents, digestive aids, remedies for constipation and circulation, antibiotics and antifungals, cough and cold preparations, vitamins and nutritional supplements, antihistamines, antivertigo agents, and over-the-counter (OTC) drugs. Additionally, BINEX Co., Ltd. maintains a co-development alliance with Genexine, Inc. focused on the creation of a COVID-19 vaccine. Founded in 1957, its headquarters are situated in Incheon, South Korea.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is 'expensive' on EV/EBITDA.
Target Price
The average target price of 053030.KQ is 9793 and suggests 54% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i